Quick Take

Nooglutyl (also spelled nooglutil; original code name ONK-10) is a synthetic “smart-drug” candidate first described in Moscow in 1990. Chemically, it stitches together two familiar molecules: L-glutamate (the brain’s main “go” signal) and 5-hydroxynicotinic acid (a close cousin of vitamin B3). In laboratory binding experiments it interacts directly with AMPA-type glutamate receptors—the fast-acting volume knobs on the brain’s learning circuits—and in rodents it consistently blunts experimentally induced memory loss and brain damage. Its single strongest human data point comes from a 124-patient Russian trial of an intravenous calcium-salt version (“Ampasse”). This guide lays out the full evidence trail—what’s measured, what’s inferred, and what’s simply unknown.

1. The Chemistry: A Two-Piece Molecule

Think of nooglutyl as a two-component construction kit:

• Piece one — L-glutamic acid: Glutamate is the nervous system’s principal excitatory neurotransmitter, the chemical that nudges neurons closer to firing. (In other contexts it’s also just an ordinary protein building block—your body makes kilos of it.)
• Piece two — 5-hydroxynicotinic acid: A chemical sibling of niacin (vitamin B3), a nutrient central to cellular energy metabolism.

Snap them together and you get nooglutyl. The design idea was elegant in its simplicity: dress up the brain’s own “accelerator” chemical in a vitamin-like coat, so the whole package could be absorbed and distributed using the body’s existing transport machinery, then act on glutamate-operated circuits once inside.

2. How It’s Thought to Work

A 30-second primer first:

• Glutamate = the accelerator pedal. Your brain balances “go” signals (excitatory) against “slow-down” signals (inhibitory). Glutamate is the lead “go” chemical.
• AMPA receptors = fast-action volume knobs. When glutamate docks onto these receptors, neurons fire quickly. They’re especially important for synaptic plasticity—the use-it-and-strengthen-it process underlying learning and memory (“neurons that fire together wire together”).
• Nooglutyl = something that turns the knob’s sensitivity up. It doesn’t press the pedal itself; it makes the receptors respond more readily when natural glutamate arrives. Compounds doing this are loosely grouped as “ampakines.”

What Was Actually Measured

There is exactly one direct receptor-binding experiment in the published record (Firstova et al., 2011). Using rat-brain membranes, it found:

A second study found that, unlike piracetam, noopept, and semax, nooglutyl did not alter metabotropic (mGluRII) binding in mouse cortex—a result consistent with it being relatively selective for AMPA-type receptors among the glutamate family. And an early behavioral study (1991) reported that the compound’s memory-rescuing action tracked its anti-scopolamine, anti-clonidine, and anti-methergoline effects, which the authors interpreted as involving cholinergic, noradrenergic, and serotonergic systems—though those pathways were inferred, not directly measured.

3. The Animal Evidence

The preclinical file is genuinely broad for a niche nootropic. Here’s the map:

3.1 The founding study (1990)

Voronina and colleagues introduced ONK-10 with a striking verdict: in mice and rats it showed “pronounced” antiamnestic (memory-protecting) and antihypoxic (low-oxygen-resisting) effects, without disturbing conditioned behavior, coordination, or orientation—and with no anxiolytic or anticonvulsant activity of its own and “low toxicity.” The 1990 abstract reports it exceeded piracetam, meclofenoxate, and demanol aceglumate on those two measures and was “not inferior” to aniracetam—a high bar, since aniracetam is an established AMPA-focused racetam. (The abstract carries no group sizes or raw numbers, so treat this as directional.)

3.2 Comparative pharmacology (1991)

A Soviet–Bulgarian collaboration reported that 50 mg/kg intraperitoneally, once daily for 5 days before training, completely blocked scopolamine-induced amnesia in mice and abolished the memory-blunting effects of clonidine and methergoline in rats—with piracetam (600–800 mg/kg, oral) and meclofenoxate (100 mg/kg, oral) as comparison drugs.

3.3 “Insult” models (mimicking real-world harm)

Across multiple institutions, nooglutyl reliably blunted memory impairment caused by:

• hypoxia (low oxygen, including high-altitude simulation),
• electroconvulsive shock,
• brain trauma,
• microwave irradiation,
• motion sickness,
• prenatal insults (below).

3.4 Developmental models (early-life exposure)

• Prenatal alcohol: offspring whose mothers received ethanol benefited from nooglutyl (25 mg/kg/day, days 8–20 of life): it prevented later deficits in open-field habituation, shuttle-box learning, EEG slow-wave activity, and cortical serotonin function.
• Intrauterine hypoxia: in offspring exposed to simulated ~8,500 m altitude before birth, the same dose improved hyperactivity, learning, passive/active avoidance, and normalized first-month growth.

3.5 Stroke models (with actual numbers)

• Hemorrhagic stroke (intracerebral hematoma): a single injection (10–20 mg/kg, given 3–4 h after injury) reduced neurological deficit, improved coordination and a passive-avoidance memory task, and cut 14-day mortality—one patent table shows untreated stroke rats at 64% mortality versus 20% with nooglutyl (20 mg/kg).
• Ischemic stroke (middle-cerebral-artery occlusion): at 72 h the infarct zone fell from ~22.5% of the affected hemisphere (controls) to ~7.6% at 10 mg/kg—better than the reference antioxidant mexidol (~9.6% at 100 mg/kg) in the same model.

3.6 Aging

In senescence-accelerated mice (a stand-in for accelerated brain aging), nooglutyl improved memory and motor function.

Summary: Across ~35 years of rodent work, the compound shows consistent anti-amnesia and reproducible neuroprotection in injury models.

4. Pharmacokinetics: What the Body Does with It

Pharmacokinetics = where the molecule goes, how long it stays, and how it’s cleared. Here’s the complete published picture:

The one true PK study (Firsov et al., 2010) gave the calcium salt as an intravenous bolus to rats and rabbits and measured blood levels by HPLC:

• Half-life: 0.73 h in rats; 2.3 h in rabbits (biphasic decay).
• Clearance: 18 mL/min/kg (rat); 15 mL/min/kg (rabbit).
• Volume of distribution: 330 mL/kg (rat); 880 mL/kg (rabbit).
• Kinetics were linear at 20–100 mg/kg but nonlinear at 500 mg/kg.

The “4-hour human half-life” is a prediction, not a measurement. Using allometric scaling (extrapolating from animal body mass), the 2010 authors predicted a human half-life of ~4 hours. That number now appears in Russian prescribing information—but no human pharmacokinetic study exists in PubMed. Treat “4 hours” as an educated estimate derived from rats and rabbits.

Oral absorption is largely unmeasured in the modern sense. A 1998 rabbit study of a tablet formulation reported “104.3% bioavailability” for a tween-80-containing tablet—but the comparator was the unformulated drug substance given by the same route, not an intravenous dose. So that figure is a relative bioavailability describing superior tablet formulation, not proof that an oral dose fully reaches the bloodstream. A 1991 study in rat offspring reported altered metabolism (a main metabolite appearing, unnamed in the abstract) after prenatal alcohol exposure. The bottom line: there is no modern, absolute oral-bioavailability number for the free acid in humans.

Why this matters for interpretation

The molecule’s short animal half-life (under ~2.3 h) hints that single doses are cleared quickly—at least by injection. The human trial used daily dosing for 15 days, and the cognitive benefit persisted for months afterward, suggesting a slowly developing, longer-lived change rather than an acute “buzz.”

5. Safety and Toxicology: What Exists vs. What’s Missing

Acute toxicity (injection, mice): Nooglutyl LD₅₀ ≈ 1200 mg/kg (95% CI 1090–1320); calcium salt ≈ 1150 mg/kg (from patent data). These are large multiples of any therapeutic exposure and align with the original “low toxicity” description—but note they describe lethality, not subtle or long-term harm.

Toxicology: One study (Kiselev 2012) reported that the calcium salt at 6.7 mg/kg (described as ~10× the intended human therapeutic dose) did not affect reproductive function and produced no embryotoxic or teratogenic effects in rats.

What is simply not known

• Zero drug–drug interaction studies.
• No safety data beyond short IV courses (roughly 15 days).

6. The Human Trial (The One Real Clinical Data Point)

The only substantial human evidence concerns Ampasse (nooglutyl calcium) in patients with chronic cerebrovascular insufficiency (chronically reduced brain blood flow with cognitive symptoms—a diagnosis used widely in Russia and the former USSR).

Design: multicenter, randomized, double-blind, placebo-controlled Phase III trial; 124 patients (ages 50–75) across 3 Russian centers; 62 per arm. Treatment: 25 mg IV daily for 15 days (5 mL of a 5 mg/mL solution, slow injection) versus saline placebo. All 124 completed.

Results:

Adverse events in the drug arm: upper respiratory infection (3), chronic bronchitis (2), fever (1), dizziness during the procedure (1), drowsiness (1)—all mild, none requiring discontinuation. The authors concluded the drug was well tolerated.

Reading this result honestly

Strengths: randomized, blinded, placebo-controlled, with a large effect on a validated cognitive scale and a plausible mechanism.

Where nooglutyl sits among related compounds

The contrast is informative: piracetam’s family shows no direct binding to the glutamate receptors tested in the same 2011 assay, whereas nooglutyl shows specific, measurable, and comparatively strong AMPA-site engagement—a rare, clean mechanistic signature among “nootropics.” That’s the scientific reason the compound remains interesting.